Anaplastic Large Cells Lymphoma Alcl Alk clinical trials

Explore recruiting anaplastic large cells lymphoma alcl alk clinical trials.

Recruiting anaplastic large cells lymphoma alcl alk studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anaplastic Large Cells Lymphoma Alcl Alk trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Anaplastic Large Cells Lymphoma Alcl Alk trials by city

Anaplastic Large Cells Lymphoma Alcl Alk clinical trials

Recruiting anaplastic large cells lymphoma alcl alk studies right now

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Also recruiting in Europe

A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS

Anaplastic Large Cells Lymphoma Alcl Alk trials by city

Other conditions